Precocious puberty and Gender Dysphoria are not a like-for-like comparison as triptorelin is actually licensed for use in precocious puberty, it’s off label for GD, hence Cass’ recommendation that it be used for GD as part of a clinical trial.
The point of delaying precocious puberty until the normal time is so that bone maturation becomes consistent with age.
Giving the same drug to kids who already have normal bone maturation for age throws that out, resulting in teens with delayed maturation for age. Hence the tooth loss and spinal issues that Sweden observed.
I think kids with Gender Dysphoria deserve better care than slapdash application of unlicensed medications with a plethora of side effects.